JP2004089004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004089004A5 JP2004089004A5 JP2002250574A JP2002250574A JP2004089004A5 JP 2004089004 A5 JP2004089004 A5 JP 2004089004A5 JP 2002250574 A JP2002250574 A JP 2002250574A JP 2002250574 A JP2002250574 A JP 2002250574A JP 2004089004 A5 JP2004089004 A5 JP 2004089004A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- diseases
- syndrome
- muscle
- cerebrospinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000029578 Muscle disease Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018300 basal ganglia disease Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000003116 Adie Syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 208000016297 Holmes-Adie syndrome Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Description
【0012】
本発明の補完療法のための栄養補助食品の成分であるRNA等は、上述のように、栄養補助食品として有用であり、脳脊髄性疾患の症状を改善するのに供されている(特公平6−69953公報(公告日 平成6年(1994)9月7日)を参照)。脳脊髄性疾患の例として、特に脳脊髄退行性疾患があり、その例としては、老人性ボケを含む痴呆症、てんかん症、痙攣発作、脳変性疾患、脳神経疾患、脳基底核疾患、小脳の変性疾患、脊髄変性疾患及び筋疾患等が挙げられる。
更に脳脊髄退行性疾患の具体的な例としてはてんかん症、痙攣発作及び脳変性疾患、例えば変性汎発性硬化症〔パレチユウスー(Pelizaeus)−メンツバツヒエル(Merzbacher)病、シヨルツ(Scholz)病、クラツベ(Krabbe)病〕、その他の先天性遺伝性疾患〔黒内障性家族性白痢、ローレンス(Lourence)−ムーン(Moon)−バーデツト(Bordet)−ビード(Bied):症候群、ガーゴイリズム〕、老年及び初老期脳疾患(老年痴呆、アルツハイマー病、ピツク病)、及び脳神経疾患例えば進行性球麻痺、進行性眼筋麻痺、遺伝性眼球振盪、アデイー(Adie)症候群、延髄空洞症、レーベル(Lebcr)病及び脳基底核疾患、例えばパーキンソン病、舞踏病疾候群、ジストニー症候群、アテトーゼ症候群、ミオクロニー症候群、振顫麻痺、小脳の変性疾患、例えば遺伝性脊髄性及び小脳性失調症、筋萎縮を伴なう遺伝性失調性、筋疾患、例えば進行性筋ジストロフイー症、重症筋無力症、週期性四肢麻痺、ミトコンドリア病(ミトコンドリア脳筋症)等が挙げられる。
本発明の補完療法のための栄養補助食品の成分であるRNA等は、上述のように、栄養補助食品として有用であり、脳脊髄性疾患の症状を改善するのに供されている(特公平6−69953公報(公告日 平成6年(1994)9月7日)を参照)。脳脊髄性疾患の例として、特に脳脊髄退行性疾患があり、その例としては、老人性ボケを含む痴呆症、てんかん症、痙攣発作、脳変性疾患、脳神経疾患、脳基底核疾患、小脳の変性疾患、脊髄変性疾患及び筋疾患等が挙げられる。
更に脳脊髄退行性疾患の具体的な例としてはてんかん症、痙攣発作及び脳変性疾患、例えば変性汎発性硬化症〔パレチユウスー(Pelizaeus)−メンツバツヒエル(Merzbacher)病、シヨルツ(Scholz)病、クラツベ(Krabbe)病〕、その他の先天性遺伝性疾患〔黒内障性家族性白痢、ローレンス(Lourence)−ムーン(Moon)−バーデツト(Bordet)−ビード(Bied):症候群、ガーゴイリズム〕、老年及び初老期脳疾患(老年痴呆、アルツハイマー病、ピツク病)、及び脳神経疾患例えば進行性球麻痺、進行性眼筋麻痺、遺伝性眼球振盪、アデイー(Adie)症候群、延髄空洞症、レーベル(Lebcr)病及び脳基底核疾患、例えばパーキンソン病、舞踏病疾候群、ジストニー症候群、アテトーゼ症候群、ミオクロニー症候群、振顫麻痺、小脳の変性疾患、例えば遺伝性脊髄性及び小脳性失調症、筋萎縮を伴なう遺伝性失調性、筋疾患、例えば進行性筋ジストロフイー症、重症筋無力症、週期性四肢麻痺、ミトコンドリア病(ミトコンドリア脳筋症)等が挙げられる。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002250574A JP2004089004A (ja) | 2002-08-29 | 2002-08-29 | アルギニンとrnaを含有する補完療法のための栄養補助食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002250574A JP2004089004A (ja) | 2002-08-29 | 2002-08-29 | アルギニンとrnaを含有する補完療法のための栄養補助食品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004089004A JP2004089004A (ja) | 2004-03-25 |
| JP2004089004A5 true JP2004089004A5 (ja) | 2005-02-03 |
Family
ID=32057369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002250574A Pending JP2004089004A (ja) | 2002-08-29 | 2002-08-29 | アルギニンとrnaを含有する補完療法のための栄養補助食品 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004089004A (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4521488B2 (ja) | 2008-08-21 | 2010-08-11 | 福美 森重 | 線維筋痛症候群の治療剤並びに筋攣縮による疼痛の治療剤 |
| JP2010070463A (ja) * | 2008-09-16 | 2010-04-02 | Fukumi Morishige | 栄養ドリンク剤 |
| JP2013049671A (ja) * | 2011-08-04 | 2013-03-14 | Fancl Corp | アスコルビン酸製剤 |
-
2002
- 2002-08-29 JP JP2002250574A patent/JP2004089004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003103583A8 (en) | METHOD OF USING BIS (POLYHYDROXYPHENYLES) AND CORRESPONDING, FIXED O-ALKYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| PT1511710E (pt) | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson | |
| WO2005080343A3 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
| WO2003041701A3 (en) | Preparation for improving the action of receptors | |
| JP2013526507A5 (ja) | ||
| AP2008A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them | |
| PL376769A1 (pl) | Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające | |
| AU2003263393A1 (en) | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | |
| CA2304965A1 (en) | ((cyclo)alkyl substituted)-gamma-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders | |
| EP2287165A3 (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| WO2008060364A3 (en) | Humani zed antibody against amyloid beta | |
| WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
| WO2008111590A3 (en) | Ampa and nmda receptor antagonists for neurodegenerative diseases | |
| JP2013528597A5 (ja) | ||
| TW200502221A (en) | Novel lactams and uses thereof | |
| TW200745135A (en) | Therapeutic agents | |
| WO2006119170A3 (en) | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| WO2007141346A3 (en) | Genes regulating intracellular cholesterol trafficking as targets for treatment of cholesterol-related diseases | |
| JP2004089004A5 (ja) | ||
| AU2002304329A1 (en) | Methods for regulation of immune responses to conditions involving mediator-induced pathology | |
| WO2004055201A3 (en) | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease | |
| WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
| WO2012030050A3 (ko) | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 | |
| WO2006058720A3 (en) | Novel compounds for the treatment of neurological disorders |